Active Ingredient(s): Copanlisib
FDA Approved: * September 14, 2017
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Aliqopa Overview

Copanlisib (BAY 80-6946), developed by Bayer, is a selective Class I phosphoinositide 3-kinase inhibitor[1] which has shown promise in Phase I/II clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.[2] The FDA awarded copanlisib orphan drug status for follicular lymphoma in February 2015.[3] Phase II clinical trials are in progress for treatment of endometrial cancer,[4] diffuse large B-cell lymphoma,[5] cholangiocarcinoma,[6] and non-Hodgkin lymphoma.[7...

Read more Aliqopa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Aliqopa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 60mg
  • Powder: 60mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Aliqopa: (1 result)

Sorted by National Drug Code
  • 50419-385 Aliqopa 15 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Bayer Healthcare Pharmaceuticals Inc.

Other drugs which contain Copanlisib or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 19 November 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.